/
/
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Chapters
- 00:05Title
- 01:04Blood and Tumor Sample Preparation
- 03:46Patient-derived Tumor Xenograft (PDTX) Injection, Bank Maintenance, and Developmental Therapeutics
- 06:40Results: PDTX Model Characterization
- 08:05Conclusion
Utilizing patient-derived tumors in a subcutaneous preclinical model is an excellent way to study the efficacy of novel therapies, predictive biomarker discovery, and drug resistant pathways. This model, in the drug development process, is essential in determining the fate of many novel anti-cancer therapies prior to clinical investigation.
